History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide (i.e. thalidomide)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostatXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to romidepsin, including cyclic tetrapeptide compoundsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, bortezomib or rituximabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib (XL184)Xx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or AZD1775 (MK-1775) are ineligible; the AZD1775 (MK-1775) investigator brochure and the temozolomide package insert can be referenced for more informationXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or TMZXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to XL184Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to CYT107Xx_NEWLINE_xXPatients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to belinostat, including hydroxamate compounds or arginineXx_NEWLINE_xXKnown severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD 1775 (MK-1775) or gemcitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs; patients who have previously received either clofarabine or bortezomib will be excludedXx_NEWLINE_xXPrior allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine (gemcitabine hydrochloride) or cisplatinXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) are ineligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax or sorafenibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or ziv-afliberceptXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 or bevacizumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 and ziv-afliberceptXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to afatinib and/or cetuximabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to GDC-0449Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or pemetrexed and cisplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or belinostatXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdRXx_NEWLINE_xXPatient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-fluorothymidineXx_NEWLINE_xXPatient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FESXx_NEWLINE_xXKnown severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinibXx_NEWLINE_xXPrior allergic reactions attributed to other monoclonal antibodiesXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)Xx_NEWLINE_xXPatients must NOT have a history of allergic reactions attributed to compounds of similar chemical or biochemical composition to cisplatin, carboplatin, etoposide, temozolomide or capecitabineXx_NEWLINE_xXKnown sensitivity to or history of allergic reactions attributed to compounds of similar chemical or biologic composition entinostat, nivolumab, or ipilimumab; history of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXPatient does not have a known allergy to compounds of similar or biologic composition as triapineXx_NEWLINE_xXHistory of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 or paclitaxelXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to onalespib or AT7519MXx_NEWLINE_xXHistory of hypersensitivity attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or osimertinib (AZD9291)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI-570 or history of anaphylaxis to any biological componentXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to methoxyamine or to pemetrexed or cisplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib and/or onalespibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970, cisplatin, or gemcitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or cisplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 (onalespib)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib (difficulty breathing, lip swelling, itching or rash)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab)Xx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatinXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or gemcitabineXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970 or irinotecanXx_NEWLINE_xXPatients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970, carboplatin, gemcitabine or to these specific compoundsXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib and MM-398; if patients have a history of allergic reactions to compounds resembling MM-398, they will be excluded from participating in the FMX MRI study, if applicableXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nelfinavirXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to LY2606368 or to its formulation are not eligibleXx_NEWLINE_xXKnown severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinibXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, ipilimumab, or blinatumomabXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and MEDI4736 or previous toxicity attributed to MEDI4736 or other PD-1 or PD-L1 directed therapy that led to drug discontinuationXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar composition, including macrolide and ketolide antibiotics, temsirolimus/other mTOR inhibitors, temozolomide or irinotecan are not eligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or atezolizumabXx_NEWLINE_xXKnown hypersensitivity to MK-3475 (pembrolizumab) or history of allergic reactions to compounds of similar chemical or biologic composition to anti-PD1 or PD-L1 antibodies or entinostatXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9291 (osimertinib) or bevacizumabXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BAL101553 are ineligibleXx_NEWLINE_xXHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdRXx_NEWLINE_xXPatients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PT2385 are ineligibleXx_NEWLINE_xX